Jessica Miller


Authored Items

Adding Daratumumab to the Treatment Regimen Improves Progression-Free Survival in Patients with Multiple Myeloma

July 2016, Vol 7, No 6 - Multiple Myeloma

Daratumumab in combination with lenalidomide and dexamethasone achieved a 63% reduction in progression-free survival (PFS) compared with lenalidomide and dexamethasone alone in patients with multiple myeloma who had received at least 1 previous line of therapy, according to study results presented at the 2016 European Hematology Association Annual Congress meeting. [ Read More ]

USPSTF Issues New Colorectal Cancer Screening Recommendations

July 2016, Vol 7, No 6 - Colorectal Cancer

New recommendations issued by the US Preventive Services Task Force (USPSTF) focus on increasing colorectal cancer screening, which, according to the task force, is “a substantially underused preventive health strategy.” Previous USPSTF guidelines recommended specific screening approaches, including colonoscopy, fecal occult blood testing, or sigmoidoscopy, for adults aged 50 through 75 years. [ Read More ]

Budget Impact Concerns Volume, Not Value: Prevention Is Key to Winning the War on Cancer

November 2016, Vol 7, No 10 - Value in Oncology

Boston, MA—Are we winning the war on cancer? According to Joshua J. Ofman, MD, MSHS, Senior Vice President, Global Value, Access and Policy, Amgen, the answer is yes. Dr Ofman discussed the economics of cancer, including challenges facing insurance providers and ways to impact the rising cost of cancer care, at the War on Cancer forum hosted by The Economist. [ Read More ]

The Impact of Policy and Politics on Health and Drug Pricing

December 2016, Vol 7, No 11 - Health Policy

Washington, DC—A panel discussion on health and drug politics took place at the Sixth Annual Conference of the Association for Value-Based Cancer Care. The expert panel included Kavita Patel, MD, Johns Hopkins Medicine, Baltimore; Dan Todd, Principal of Todd Strategy, Washington, DC; and Liz Fowler, Vice President, Global Health Policy, Johnson & Johnson. The panel discussed what is working in healthcare, what is not, and where cancer care fits into it all. [ Read More ]

Navigating Patient Assistance Programs

December 2016, Vol 7, No 11 - Patient Support Services

Washington, DC—In the past 6 years, more than $4 billion in charitable assistance has been dedicated to patients in need. In 2015 alone, the Patient Access Network (PAN) Foundation provided $950 million in cancer care support. The only people with deep enough pockets to support this type of assistance are drug manufacturers, adding to an already complicated regulatory environment for charitable assistance programs, said Daniel J. Klein, President and Chief Executive Officer, PAN Foundation, at the Sixth Annual Conference of the Association for Value-Based ­Cancer Care. [ Read More ]